MA27011A1 - Derives de dihydro-benzo[b] [1,4] diazepine-2-one utilises comme antagonistes i de mglur2 - Google Patents
Derives de dihydro-benzo[b] [1,4] diazepine-2-one utilises comme antagonistes i de mglur2Info
- Publication number
- MA27011A1 MA27011A1 MA27345A MA27345A MA27011A1 MA 27011 A1 MA27011 A1 MA 27011A1 MA 27345 A MA27345 A MA 27345A MA 27345 A MA27345 A MA 27345A MA 27011 A1 MA27011 A1 MA 27011A1
- Authority
- MA
- Morocco
- Prior art keywords
- mglur2
- diazepine
- benzo
- antagonists
- dihydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01109126 | 2001-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27011A1 true MA27011A1 (fr) | 2004-12-20 |
Family
ID=8177127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27345A MA27011A1 (fr) | 2001-04-12 | 2003-10-08 | Derives de dihydro-benzo[b] [1,4] diazepine-2-one utilises comme antagonistes i de mglur2 |
Country Status (38)
Country | Link |
---|---|
US (1) | US6548495B2 (fr) |
EP (1) | EP1379522B1 (fr) |
JP (1) | JP4043953B2 (fr) |
KR (1) | KR100566178B1 (fr) |
CN (1) | CN1268626C (fr) |
AR (1) | AR035456A1 (fr) |
AT (1) | ATE287883T1 (fr) |
AU (1) | AU2002310912B2 (fr) |
BG (1) | BG108253A (fr) |
BR (1) | BR0208887A (fr) |
CA (1) | CA2441771C (fr) |
CZ (1) | CZ20033002A3 (fr) |
DE (1) | DE60202761T2 (fr) |
DK (1) | DK1379522T3 (fr) |
EC (1) | ECSP034796A (fr) |
ES (1) | ES2235044T3 (fr) |
GT (1) | GT200200072A (fr) |
HK (1) | HK1068339A1 (fr) |
HR (1) | HRP20030791B1 (fr) |
HU (1) | HUP0400991A3 (fr) |
IL (2) | IL158021A0 (fr) |
JO (1) | JO2273B1 (fr) |
MA (1) | MA27011A1 (fr) |
MX (1) | MXPA03009317A (fr) |
MY (1) | MY130369A (fr) |
NO (1) | NO325300B1 (fr) |
NZ (1) | NZ528345A (fr) |
PA (1) | PA8543201A1 (fr) |
PE (1) | PE20021072A1 (fr) |
PL (1) | PL367086A1 (fr) |
PT (1) | PT1379522E (fr) |
RU (1) | RU2270197C2 (fr) |
SI (1) | SI1379522T1 (fr) |
SK (1) | SK13692003A3 (fr) |
UY (1) | UY27259A1 (fr) |
WO (1) | WO2002083665A1 (fr) |
YU (1) | YU79103A (fr) |
ZA (1) | ZA200307242B (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1224175T3 (da) * | 1999-10-15 | 2004-07-12 | Hoffmann La Roche | Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister |
JP5005343B2 (ja) * | 2003-07-25 | 2012-08-22 | エフ.ホフマン−ラ ロシュ アーゲー | 急性及び/又は慢性神経障害の治療のためのmGluR2アンタゴニストとAChEインヒビターの併用 |
ATE400557T1 (de) | 2004-11-05 | 2008-07-15 | Hoffmann La Roche | Verfahren zur herstellung von isonikotinsäurederivaten |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
CA2684760A1 (fr) * | 2007-04-19 | 2008-10-30 | F. Hoffmann-La Roche Ag | Derives du dihydro-benzo[b][1,4]diazepine-2-one sulfamide |
EA019085B1 (ru) | 2007-09-14 | 2014-01-30 | Янссен Фармасьютикалз, Инк. | 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны |
NZ584145A (en) | 2007-09-14 | 2012-03-30 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones |
EP2205565B1 (fr) * | 2007-09-14 | 2013-04-17 | Janssen Pharmaceuticals, Inc. | 4-phényl-1h-pyridin-2-ones 1,3-di-substituées |
MX2010005110A (es) | 2007-11-14 | 2010-09-09 | Ortho Mcneil Janssen Pharm | Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2. |
ES2439291T3 (es) | 2008-09-02 | 2014-01-22 | Janssen Pharmaceuticals, Inc. | Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos |
US8697689B2 (en) | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
MX2011005242A (es) | 2008-11-28 | 2011-09-06 | Ortho Mcneil Janssen Pharm | Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos. |
CA2760259C (fr) | 2009-05-12 | 2018-05-01 | Janssen Pharmaceuticals, Inc. | Derives de la 1,2,4-triazolo [4,3-a] pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2 |
MY161325A (en) | 2009-05-12 | 2017-04-14 | Janssen Pharmaceuticals Inc | 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
JP5852664B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
CN103298809B (zh) | 2010-11-08 | 2016-08-31 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
EP2602248A1 (fr) | 2011-12-05 | 2013-06-12 | University Of Leicester | Nouveaux composés pyrroliques |
AU2013336863A1 (en) | 2012-10-23 | 2015-03-19 | F. Hoffmann-La Roche Ag | MGlu2/3 antagonists for the treatment of autistic disorders |
UA114950C2 (uk) * | 2013-02-28 | 2017-08-28 | Ейсей Р Енд Д Менеджмент Ко., Лтд. | ТЕТРАГІДРОІМІДАЗО[1,5-d][1,4]ОКСАЗЕПІНОВА ПОХІДНА |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
ME03518B (fr) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Combinaisons comprenant des modulateurs allostériques positifs de sous-type 2 de récepteurs glutamatergiques métabotropes et leur utilisation |
WO2015110435A1 (fr) | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinaisons comprenant des modulateurs allostériques positifs ou des agonistes orthostériques de sous-type 2 de récepteur glutamatergique métabotrope, et leur utilisation |
KR20160143853A (ko) | 2014-04-23 | 2016-12-14 | 에프. 호프만-라 로슈 아게 | 지적 장애의 치료를 위한 mglu2/3 길항제 |
WO2015191630A1 (fr) * | 2014-06-10 | 2015-12-17 | Sanford-Burnham Medical Research Institute | Modulateurs allostériques négatifs (nam) du récepteur métabotropique du glutamate et utilisations de ceux-ci |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1210338A2 (fr) * | 1999-08-05 | 2002-06-05 | IGT Pharma Inc. | Derives de 1,4 benzodiazepine utiles dans le traitement de maladies liees au systeme nerveux central |
RU2259360C2 (ru) * | 1999-10-15 | 2005-08-27 | Ф.Хоффманн-Ля Рош Аг | Производные бензодиазепина и лекарственное средство, их содержащее |
DK1224175T3 (da) * | 1999-10-15 | 2004-07-12 | Hoffmann La Roche | Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister |
-
2002
- 2002-04-02 PT PT02735209T patent/PT1379522E/pt unknown
- 2002-04-02 AU AU2002310912A patent/AU2002310912B2/en not_active Ceased
- 2002-04-02 CZ CZ20033002A patent/CZ20033002A3/cs unknown
- 2002-04-02 MX MXPA03009317A patent/MXPA03009317A/es active IP Right Grant
- 2002-04-02 DK DK02735209T patent/DK1379522T3/da active
- 2002-04-02 IL IL15802102A patent/IL158021A0/xx unknown
- 2002-04-02 WO PCT/EP2002/003643 patent/WO2002083665A1/fr active IP Right Grant
- 2002-04-02 AT AT02735209T patent/ATE287883T1/de active
- 2002-04-02 KR KR1020037013398A patent/KR100566178B1/ko not_active IP Right Cessation
- 2002-04-02 ES ES02735209T patent/ES2235044T3/es not_active Expired - Lifetime
- 2002-04-02 NZ NZ528345A patent/NZ528345A/en unknown
- 2002-04-02 YU YU79103A patent/YU79103A/sh unknown
- 2002-04-02 BR BR0208887-8A patent/BR0208887A/pt active Search and Examination
- 2002-04-02 SI SI200230075T patent/SI1379522T1/xx unknown
- 2002-04-02 PL PL02367086A patent/PL367086A1/xx not_active Application Discontinuation
- 2002-04-02 SK SK1369-2003A patent/SK13692003A3/sk unknown
- 2002-04-02 EP EP02735209A patent/EP1379522B1/fr not_active Expired - Lifetime
- 2002-04-02 JP JP2002581420A patent/JP4043953B2/ja not_active Expired - Fee Related
- 2002-04-02 HU HU0400991A patent/HUP0400991A3/hu not_active Application Discontinuation
- 2002-04-02 CA CA002441771A patent/CA2441771C/fr not_active Expired - Fee Related
- 2002-04-02 DE DE60202761T patent/DE60202761T2/de not_active Expired - Lifetime
- 2002-04-02 RU RU2003130648/04A patent/RU2270197C2/ru not_active IP Right Cessation
- 2002-04-02 CN CNB028078217A patent/CN1268626C/zh not_active Expired - Fee Related
- 2002-04-03 US US10/116,597 patent/US6548495B2/en not_active Expired - Lifetime
- 2002-04-09 PA PA20028543201A patent/PA8543201A1/es unknown
- 2002-04-10 AR ARP020101313A patent/AR035456A1/es not_active Application Discontinuation
- 2002-04-10 PE PE2002000299A patent/PE20021072A1/es not_active Application Discontinuation
- 2002-04-10 JO JO200233A patent/JO2273B1/en active
- 2002-04-11 MY MYPI20021346A patent/MY130369A/en unknown
- 2002-04-11 GT GT200200072A patent/GT200200072A/es unknown
- 2002-04-11 UY UY27259A patent/UY27259A1/es not_active Application Discontinuation
-
2003
- 2003-09-16 ZA ZA200307242A patent/ZA200307242B/en unknown
- 2003-09-18 IL IL158021A patent/IL158021A/en not_active IP Right Cessation
- 2003-10-01 HR HR20030791A patent/HRP20030791B1/xx not_active IP Right Cessation
- 2003-10-08 EC EC2003004796A patent/ECSP034796A/es unknown
- 2003-10-08 NO NO20034496A patent/NO325300B1/no unknown
- 2003-10-08 MA MA27345A patent/MA27011A1/fr unknown
- 2003-10-10 BG BG108253A patent/BG108253A/bg unknown
-
2005
- 2005-01-17 HK HK05100429A patent/HK1068339A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27011A1 (fr) | Derives de dihydro-benzo[b] [1,4] diazepine-2-one utilises comme antagonistes i de mglur2 | |
FR20C1039I2 (fr) | Derives de l'uk-2a | |
MA27012A1 (fr) | Derives de dihydro-benzo [b] [1,4] diazepin-2-one en tant qu'antagonistes ii de mglur2 | |
MA26344A1 (fr) | Derives 1,8-naphtyridine utilises comme antidiabetiques | |
FR07C0057I2 (fr) | Derives de pleuromutiline utilises comme agents antimicrobiens | |
DZ3506A1 (fr) | Derives de pyrrole utilises comme agents pharmaceutiques | |
FR08C0007I2 (fr) | Derives du triazolyltropane utilises comme modulateurs de ccr5 | |
NO20043022L (no) | 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister | |
NO20026252L (no) | Aza-broforbundet-bicykliske aminosyrederivater som <alfa>4 integrin antagonister | |
DZ3327A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
FR2813756B1 (fr) | Dilueur pour la conservation de spermatozoides de porcins | |
MA26543A1 (fr) | Derives de pyrrolopyrrolone comme inhibiteurs d'elastase de neutrophiles. | |
PT1216250E (pt) | Derivados propilicos substituidos de tienoisoxazolil- e tienilpirrazolil-fenoxi uteis como antagonistas d4 | |
MA26064A1 (fr) | Derives 1,4 de piperazine substitues utilises comme bloqueurs a1-adrenocepteur uro-selectifs. | |
MA26778A1 (fr) | Derives de biphenyl utilises comme recepteurs de neurokinine-1. | |
DE60224221D1 (de) | Aminotetralinderivate, antagonisten von muscarinrezeptoren | |
FR2833596B1 (fr) | Procede de preparation de derives d'echinocandine | |
AR028607A1 (es) | Derivados de 1,4-diazepan-2,5-diona | |
MA26844A1 (fr) | Nouveaux derives de la thiazolidinedione comme agents antidiabetiques | |
ITMI20001695A0 (it) | Procedimento per la preparazione di composizioni organico-sili-coniche. | |
MA27240A1 (fr) | Derives d'imidazoquinoleine | |
NO20011309D0 (no) | Benzotieno [3,2-c]pyridiner som<alfa>2-antagonister | |
FR2819255B1 (fr) | Derives chimiques et leur application comme agent antitelomerase | |
FR2825090B1 (fr) | Derives chimiques et leur application comme agent antitelomerase | |
ITMI20011344A0 (it) | Procedimento per la preparazione di 1,3-diossolan-2-oni |